Use search to browse all 100+ peptides
Emideltide, DSIP nonapeptide, Delta sleep-inducing peptide
A neuropeptide that induces delta sleep, reduces stress, modulates hormone release, and exhibits antioxidant effects in various physiological processes.
Pu. L P LP; Dubois. P M PM
Error: Malformed JSON response.
Giusti. M M; Carraro. A A; Porcella. E E; Valenti. S S; Nicora. D D; Sessarego. P P; Giordano. G G
In a small study of eight healthy women, giving delta sleep‑inducing peptide (DSIP) at a dose that changes heart‑rate patterns did not change the levels of growth hormone or prolactin, either on its own or when combined with an arginine boost. The peptide also didn’t shift the normal daily rhythm of these hormones.
Sillard. R R; Schulz-Knappe. P P; Vogel. P P; Raida. M M; Bensch. K W KW; Forssmann. W G WG; Mutt. V...
The study describes a new 77‑amino‑acid peptide from pig brain that reacts with antibodies made for a tiny sleep‑inducing peptide, but it doesn’t show any real‑world use or health benefit.
Charnay. Y Y; Golaz. J J; Vallet. P G PG; Bouras. C C
Researchers created antibodies that bind to the peptide DSIP and used them to map where DSIP is located in rat brain tissue. They discovered DSIP in specific brain regions and that its presence differs in other rodent species, but the work does not give any practical advice on using DSIP for health or performance.
Kopp. N N; Najimi. M M; Champier. J J; Chigr. F F; Charnay. Y Y; Epelbaum. J J; Jordan. D D
Error: Malformed JSON response.
Myers. R D RD
The paper only counts how many scientific papers have been written about brain‑active peptides over the past 60 years; it doesn’t test any peptide on people or give dosing tips.
Johnson. B A BA; Aswad. D W DW
The paper is about a lab method for measuring a specific chemical change (isoaspartate) in proteins, using an enzyme and a special peptide called DSIP. It tells scientists how much enzyme and other chemicals they need for accurate measurements, but it doesn't give any advice on how to use DSIP as a supplement or its health effects.
Graf. M V MV; Schoenenberger. G A GA
Error: Malformed JSON response.
Yehuda. S S; Carasso. R L RL
Error: Malformed JSON response.
Vallet. P G PG; Charnay. Y Y; Bouras. C C; Constantinidis. J J
DSIP and CLIP [ACTH(18-39)] immunoreactive (IR) neurons and fibers were examined in the human hypophysis and pituitary stalk using immunmohistofluorescence and peroxidase-antiperoxidase methods. Double-stained and adjacent stained sections demonstrate that DSIP is colocalized in about 75% of CLIP-IR-like cells in the anterior pituitary and in residual intermediate lobe cells. Only few CLIP-IR-like fibers are observed in the posterior lobe. On the contrary, a high density of DSIP-IR fibers is visualized in the stalk. It is suggested that DSIP acts as a sleep promoting factor (one of many other actions) and that CLIP increases the paradoxical sleep, so that these two peptides could play a role in the regulating system of the sleep-waking cycle.
Obál. F F; Kovalzon. V M VM; Kalikhevich. V N VN; Török. A A; Alföldi. P P; S&#x...
DSIP and its analogues, [D-Trp1]-DSIP, [D-Tyr1]-DSIP, and [D-Trp1]-DSIP1-6, were injected ICV (7 nmol/kg) into rats at dark onset, and the sleep-wake activity was recorded during the 12-hr dark period and the subsequent 12-hr light period. The effects were evaluated with respect to baseline records obtained after artificial CSF injections. DSIP did not increase sleep, whereas both [D-Trp1]-DSIP and [D-Tyr1]-DSIP promoted sleep in the first part of the night. [D-Trp1]-DSIP1-6 had a prompt arousing effect. It is suggested that the sleep-promoting analogues act by facilitating slight endogenous sleep tendencies at some time after dark onset, while DSIP is degraded quickly and is therefore not effective. The increase of W after [D-Trp1]-DSIP1-6 may indicate that DSIP contains a fragment with an arousing effect. The results corroborate the notion that the active DSIP molecule has a pseudo-cyclic structure.
Yehuda. S S; Caspy. T T; Carasso. R L RL
Groups of control and Area Postrema rats were treated with 0.1 mg/kg, i.p., DSIP or with saline, at 06:00, 09:00, 12:00, 15:00, 18:00, 21:00, 24:00, and at 03:00. Colonic temperature, blood pressure, and heart rate were measured 30 min after treatment. DSIP induced a shift in the hyperthermic cycle of control rats, but was unable to modify the noncyclic hypothermia found among Area Postrema-lesioned rats. Furthermore, DSIP caused a decrease in the blood pressure level of control rats, but had no such effect on the already depressed level of blood pressure in the Area Postrema-lesioned rats. Finally, DSIP decreased the heart rate of control rats and significantly antagonized the elevated heart rate observed in the Area Postrema-lesioned rats. The data do not permit us directly to relate the physiological change induced by DSIP to its sleep-promoting effects.
Lesch. K P KP; Widerlöv. E E; Ekman. R R; Laux. G G; Schulte. H M HM; Pfüller. H H; Beckma...
Twenty-four subjects (12 patients with major depressive disorder and 12 controls matched for sex and age) received 100 micrograms synthetic human corticotropin-releasing hormone (hCRH) as an iv bolus dose. Healthy subjects exhibited a slight, but sustained, increase of plasma delta sleep-inducing peptide (DSIP) concentrations, whereas a marked reduction of DSIP levels was found in depressives. Compared to controls, depressed patients showed a significant attenuation of corticotropin (ACTH) responses, whereas cortisol secretion in response to hCRH was normal. Basal DSIP and cortisol concentrations were highly correlated and were higher in depressives than in controls. Both were negatively correlated with the DSIP responses to hCRH. These findings are compatible with the hypothesis that hypothalamic-pituitary-adrenal (HPA) overactivity in the depressive state is primarily due to central hypersecretion of CRH and support the view of a modulatory function of DSIP in the complex regulatory mechanism of the HPA system and of its pathophysiological significance for aberrant HPA axis function in major depressive disorder.
Charnay. Y Y; Bouras. C C; Vallet. P G PG; Golaz. J J; Guntern. R R; Constantinidis. J J
This study mapped where a peptide called delta sleep‑inducing peptide (DSIP) is found in the rabbit brain. It mainly shows up in parts of the hypothalamus and pituitary that control hormone release, with few actual cell bodies but many nerve fibers in those areas.
Ahlman. H H; Ahlund. L L; Nilsson. O O; Dahlström. A A; Bjartell. A A; Ekman. R R
The study found that a peptide called delta sleep‑inducing peptide (DSIP) is present together with serotonin in certain gut tumor cells, but it doesn't seem useful as a disease marker and doesn't change when serotonin levels are boosted.
Kastin. A J AJ; Dickson. J C JC; Fischman. A J AJ
Delta sleep-inducing peptide-like immunoreactivity (DSIP-LI) was measured by radioimmunoassay (RIA) in individual brain areas of rats running a 12-choice maze. One of the areas found to contain a high level of DSIP-LI was the thalamus, where a distinct peak of immunoreactivity eluted at the position of the synthetic DSIP nonapeptide after high performance liquid chromatography (HPLC). On each of the two days of testing, DSIP-LI in the thalamus correlated significantly with running times in the maze. The results suggest an association of behavior with the levels of peptide in a region of the brain.
Dick. P P; Costa. C C; Fayolle. K K; Grandjean. M E ME; Khoshbeen. A A; Tissot. R R
The hypothesis for this therapeutic use of delta sleep-inducing peptide (DSIP) was based on several animal studies conducted by Tissot. He showed that morphine, alcohol, pentobarbital as well as DSIP, when injected directly into the bulbo-mesencephalo-thalamic recruiting system, induced slow-wave sleep with numerous spindles. In all cases, this effect was reversed by Naloxone. Thus, it has been postulated that DSIP possesses an agonistic activity on opiate receptors and might be of value in the treatment of withdrawal syndromes. Therefore, DSIP was administered intravenously to 107 inpatients presenting with symptoms of alcohol (n = 47) or opiate (n = 60) withdrawal. The assessment of effect was based on the clinical evaluation by the physician and the nursing staff. Approximately 13% of the patients from the first and 22% from the second group did not fulfil the requirements for the evaluation of treatment. In, respectively, 97 and 87% of opiate and alcohol addicts, the clinical symptoms and signs disappeared after DSIP administration or improved markedly and rapidly. Anxiety, however, was slower to decrease. On the average, the clinical symptomatology had a more prolonged course and a higher number of DSIP injections were required for opiate addicts than for alcoholics. Tolerance to the DSIP treatment was good, aside from headaches reported by a few patients.
Graf. M V MV; Kastin. A J AJ; Fischman. A J AJ
Error: Malformed JSON response.
Graf. M V MV; Kastin. A J AJ
The presence of delta sleep-inducing peptide (DSIP) in brain has been shown by radioimmunoassay (RIA) and by immunocytochemistry. We now describe the occurrence of DSIP-like material in the peripheral organs of the rat as measured by RIA. Tissue from 12 areas was extracted with water, and the amounts of immunoreactive material found to be between 86 pg/mg tissue (muscle) and 849 pg/mg (stomach). Recoveries of about 80% of added DSIP were achieved at tissue concentrations of 1 mg/ml or less. This percentage was reduced in liver at higher concentrations. The percentage of small peptide adsorbed by charcoal was greatly increased at lower tissue concentrations in all organs. This effect was significant and linear. Chromatography on columns of Sephadex G-15 and G-25 showed immunoreactive material mostly larger than DSIP. Digestion with trypsin, however, produced small immunoreactive peptides with only a minimal reduction in total immunoreactivity. Thus, DSIP-like material is widespread in peripheral tissues and appears to exist mainly in a large form, probably bound to protein, that can be reduced in size by tryptic digestion and can be dissociated at lower concentrations of tissue to yield small immunoreactive peptides.
Banks. W A WA; Kastin. A J AJ; Selznick. J K JK
Error: Malformed JSON response.